The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The role of early molecular predictor in transplant-eligible chronic myelogenous leukemia

  • Kim, Sung-Hyun (Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine)
  • Received : 2016.12.19
  • Published : 2017.01.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016;128:17-23. https://doi.org/10.1182/blood-2016-01-694265
  2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884. https://doi.org/10.1182/blood-2013-05-501569
  3. Lee SE, Choi SY, Kim SH, et al. BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia. Korean J Intern Med 2017;32:125-136. https://doi.org/10.3904/kjim.2015.187
  4. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase- polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97:1560-1565. https://doi.org/10.1182/blood.V97.6.1560
  5. Asnafi V, Rubio MT, Delabesse E, et al. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2006;20:793-799. https://doi.org/10.1038/sj.leu.2404170
  6. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37. https://doi.org/10.1182/blood-2006-01-0092
  7. Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006;107:4171-4176. https://doi.org/10.1182/blood-2005-08-3320
  8. Varda-Bloom N, Danylesko I, Shouval R, et al. Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Oncotarget 2016 Nov 18 [Epub]. http://dx.doi.org/10.18632/oncotarget.13439.